Table 1

Factors associated with adhesion to COVID-19 vaccination

Acceptance of COVID-19 vaccine
(Pfizer/BioNTech)
Acceptance of COVID-19 vaccine
(any)
Univariable analysisMultivariable analysisUnivariable analysisMultivariable analysis
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Age0.99 (0.97 to 1.03)0.811.01 (0.99 to 1.03)0.49
Age ≥700.51 (0.17 to 1.45)0.190.42 (0.13 to 1.30)0.130.56 (0.25 to 1.28)0.17
Age <500.74 (0.30 to 1.85)0.520.59 (0.31 to 1.12)0.100.26 (0.08 to 0.83)0.02
Male gender2.22 (0.73 to 6.79)0.162.57 (0.82 to 8.08)0.111.56 (0.79 to 3.09)0.194.13 (0.89 to 19.13)0.06
Smoking0.97 (0.20 to 4.71)0.971.35 (0.42 to 4.34)0.62
BMI1.06 (0.91 to 1.24)0.450.95 (0.85 to 1.05)0.30
BMI >301.58 (0.18 to 13.86)0.680.35 (0.09 to 1.32)0.120.29 (0.06 to 1.40)0.12
Hypertension0.96 (0.30 to 3.08)0.951.62 (0.67 to 3.89)0.28
Diabetes0.36 (0.07 to 1.99)0.240.35 (0.08 to 1.49)0.15
Rheumatic diagnosis
 RAReferenceReference
 PsA3.17 (0.70 to 14.46)0.141.12 (0.51 to 2.47)0.78
 SpA1.41 (0.44 to 4.50)0.570.81 (0.38 to 1.75)0.60
 Vasculitis1.01 (0.21 to 4.89)0.991.06 (0.32 to 3.52)0.93
Disease duration0.99 (0.99 to 1.00)0.710.99 (0.99 to 1.00)0.37
Use of PDN0.88 (0.37 to 2.10)0.770.79 (0.43 to 1.45)0.45
PDN dose1.01 (0.90 to 1.29)0.411.03 (0.93 to 1.14)0.55
PDN dose ≥5 mg/day2.28 (0.65 to 8.01)0.193.36 (0.86 to 13.21)0.081.14 (0.56 to 2.34)0.71
Use of csDMARDs2.20 (0.83 to 5.82)0.112.19 (1.03 to 5.60)0.041.75 (0.93 to 3.28)0.083.90 (0.92 to 16.56)0.07
Type of b/tsDMARD
 Cytokine inhibitorReference0.22 (0.04 to 1.15)0.07Reference
 CTLA4-Ig0.95 (0.30 to 3.05)0.931.19 (0.37 to 3.87)0.77
 Anti-CD200.26 (0.06 to 1.12)0.071.18 (0.52 to 2.71)0.69
 JAK inhibitor1.79 (0.22 to 14.47)0.580.86 (0.21 to 3.47)0.83
 PDE4 inhibitor0.73 (0.18 to 3.07)0.67
Influenza vaccination0.67 (0.22 to 2.41)0.590.59 (0.17 to 1.35)0.25
  • The associations between demographic and clinical variables and acceptance of COVID-19 vaccine were investigated by means of univariable and multivariable logistic models including non-collinear variables with p<0.2 at the univariable analysis. Results are presented as ORs and 95% CIs. All analyses were conducted using MedCalc V.12.7.0.0, and the level of significance was set at 0.05.

  • BMI, body mass index; b/ts, biological/targeted synthetic; cs, conventional synthetic; CTLA4, cytotoxic T-lymphocyte antigen 4; DMARD, disease-modifying antirheumatic drug; JAK, Janus kinase; PDE4, phosphodiesterase 4; PDN, prednisone; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis.